ArticleStroke2019
Fn-EDA (Fibronectin Containing Extra Domain A) in the Plasma, but Not Endothelial Cells, Exacerbates Stroke Outcome by Promoting Thrombo-Inflammation.
Article in Stroke, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 34 citations in OpenAlex.
- An integrative clinical and bioinformatic analysis identifies MicroRNAs as biomarkers of ischemic stroke severity.Scientific reports · 2026Article
- Dynamic serum lactate dehydrogenase monitoring during the acute phase and association with in-hospital all-cause mortality risk in large vessel occlusion acute ischemic stroke patients.European journal of medical research · 2025Article
- Extracellular matrix: unlocking new avenues in cancer treatment.Biomarker research · 2025Review
- The Role of Thrombo-inflammation in Ischemic Stroke: Focus on the Manipulation and Clinical Application.Molecular neurobiology · 2025Review
- Serum Fibronectin Levels Increased Significantly Following the Administration of an Inactivated SARS-CoV-2 Vaccine: A Prospective Observational Study.International journal of general medicine · 2025Article
- Changes in various forms of fibronectin in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass - a prospective, observational study.Scientific reports · 2024Observational
- Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1.Genes & diseases · 2024Article
- Recent Advances on the Molecular Mechanism and Clinical Trials of Venous Thromboembolism.Journal of inflammation research · 2023Review
- Explainable Artificial Intelligence Helps in Understanding the Effect of Fibronectin on Survival of Sepsis.Cells · 2022Article
- Article
- A narrative review of long noncoding RNA: insight into neural ischemia/reperfusion mediated by two pathophysiological processes of injury and repair.Annals of translational medicine · 2022Review
- Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden ofFrontiers in oncology · 2022Article
- Prospects of Therapeutic Target and Directions for Ischemic Stroke.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Controlling cardiac fibrosis through fibroblast state space modulation.Cellular signalling · 2021Review
- Cellular fibronectin promotes deep vein thrombosis in diet-induced obese mice.Journal of thrombosis and haemostasis : JTH · 2021Article
- Asthma and stroke: a narrative review.Asthma research and practice · 2021Review
- Large-Scale Multi-omic Analysis of COVID-19 Severity.Cell systems · 2021Article
- Similarities and Differences in Extracellular Vesicle Profiles between Ischaemic Stroke and Myocardial Infarction.Biomedicines · 2020Article
- Blowing up Neural Repair for Stroke Recovery: Preclinical and Clinical Trial Considerations.Stroke · 2020Review
- Neuroinflammation and fibrosis in stroke: The good, the bad and the ugly.Journal of neuroimmunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Background and Purpose- Cellular Fn-EDA (fibronectin containing extra domain A) is expressed in activated endothelial cells and elevated in circulation in patients with cardiovascular diseases. Although global deficiency of Fn-EDA in mice improves stroke outcome, the specific contribution of plasma versus endothelium Fn-EDA in stroke outcome is currently unknown. We investigated the role of plasma versus endothelial Fn-EDA in stroke exacerbation in the comorbid condition of hyperlipidemia. Methods- We generated novel plasma Fn-EDA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.